Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-07-12
2011-07-12
Ha, Julie (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S183000, C530S317000, C530S323000
Reexamination Certificate
active
07977304
ABSTRACT:
Compounds which are FK228 analogues of the general formula (I) or (I′), isosteres thereof and pharmaceutically acceptable salts thereof are found to inhibit HDAC wherein R1, R2, R3and R4are the same or different and represent an amino acid side chain moiety and each R6is the same or different and represents hydrogen or C1-C4alkyl.
REFERENCES:
patent: 4977138 (1990-12-01), Okuhara et al.
patent: 5798097 (1998-08-01), McKenzie et al.
patent: 2007/0190022 (2007-08-01), Bacopoulos et al.
patent: 1 302 476 (2003-04-01), None
patent: WO 01/42282 (2001-06-01), None
patent: WO 2005/000332 (2005-01-01), None
Chuang D-M, Leng Y, Marinova Z, Kim H-J, Chiu C-T, “Multiple roles of HDAC inhibition in neurodegenerative conditions,” Cell Press, 2009, 32(11): 591-601.
Definition of isostere from http://dictionary.reference.com/browse/isostere, p. 1. Accessed Sep. 10, 2010.
Dementia from Merck manual, pp. 1-17. Accessed Jul. 29, 2009.
Mattson MP, “Pathways towards and away from Alzheimer's disease,” Nature, 2004, 430: 631-639.
Introduction to Cancer from Merck manual, p. 1. Accessed Mar. 5, 2008.
Clinical Aspects of Cancer from Merck manual, pp. 1-4. Accessed Mar. 5, 2008.
Auerbach R, Akhtar N, Lewis RL, Shinners BL, “Angiogenesis assays: Problems and pitfalls,” Cancer and Metastasis Reviews, 2000, 19: 167-172.
Gura T, “Systems for Identifying New Drugs Are Often Faulty,” Science, 1997, 278: 1041-1042.
Jain RK, “Barriers to drug delivery in solid tumors,” Scientific American, 1994, 58-65.
Yurek-George, Alexander et al. ((2004) “Total Synthesis of Spiruchostatin A, a Potent Histone Deacetylase Inhibitor”J. Am. Chem. Soc. 126(4):1030-1031.
Cecil Alexander Richard Liam
Ganesan Arasu
Packham Graham Keith
Yurek-George Alexander
Ha Julie
Saliwanchik Lloyd & Eisenschenk
University of Southampton Highfield
LandOfFree
FK 228 derivates as HDAC inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with FK 228 derivates as HDAC inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FK 228 derivates as HDAC inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2652415